TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TESARO Inc (NASDAQ TSRO) traded down $1.46 during mid-day trading on Tuesday, reaching $84.98. The company’s stock had a trading volume of 488,704 shares, compared to its average volume of 1,021,704. TESARO Inc has a 1 year low of $79.03 and a 1 year high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. During the same quarter in the previous year, the business earned ($1.72) earnings per share. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. research analysts anticipate that TESARO Inc will post -8.16 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its position in TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares during the period. Vanguard Group Inc. grew its position in TESARO by 2.1% during the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares during the period. State Street Corp grew its position in TESARO by 17.9% during the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after acquiring an additional 177,057 shares during the period. Janus Henderson Group PLC grew its position in TESARO by 24.9% during the third quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after acquiring an additional 178,406 shares during the period. Finally, BB Biotech AG grew its position in TESARO by 6.5% during the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after acquiring an additional 53,408 shares during the period.

A number of equities analysts have recently weighed in on TSRO shares. Morgan Stanley reissued an “overweight” rating and issued a $165.00 price target (down from $181.00) on shares of TESARO in a report on Wednesday, November 8th. Cann reissued a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Friday, September 8th. Citigroup reissued a “buy” rating and issued a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Zacks Investment Research lowered TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a research note on Monday, September 11th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $159.39.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/insider-selling-tesaro-inc-tsro-svp-sells-829-shares-of-stock.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.